The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy

Rev Gastroenterol Mex (Engl Ed). 2020 Apr-Jun;85(2):190-206. doi: 10.1016/j.rgmx.2019.11.003. Epub 2020 Feb 21.
[Article in English, Spanish]

Abstract

More than 30 million persons worldwide take nonsteroidal anti-inflammatory drugs (NSAIDs) on a daily basis, and annual consumption is increasing. In addition to their analgesic and anti-inflammatory properties, NSAIDs also produce well-known gastrointestinal adverse events. There is no consensus in Mexico on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy, and so the Asociación Mexicana de Gastroenterología brought together a group of experts to establish useful recommendations for the medical community. Thirty-three recommendations were formulated in the present consensus, highlighting the fact that the risk for NSAID-induced gastrointestinal toxicity varies according to the drug employed and its pharmacokinetics, which should be taken into account at the time of prescription. The risk factors for gastroduodenal complications due to NSAIDs are: a history of peptic ulcer, age above 65 years, high doses of NSAIDs, Helicobacter pylori infection, and the presence of severe comorbidities. The symptoms and gastroduodenal damage induced by NSAIDs vary, ranging from an asymptomatic course to the presentation of iron-deficiency anemia, bleeding, stricture, and perforation. Capsule endoscopy and enteroscopy are direct diagnostic methods in NSAID enteropathy. Regarding prevention, the minimum dose of an NSAID needed to achieve the desired effect, administered for the shortest period of time, is the recommendation. Finally, proton pump inhibitors are the gold standard for the prophylaxis and treatment of gastroduodenal effects, but they are not useful in enteropathy.

Keywords: Anti-inflammatory; Antiinflamatorio; Enteropathy; Enteropatía; Gastropathy; Gastropatía; Mexico; México; No Esteroideo; Nonsteroidal; Ulcer; Úlcera.

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Age Factors
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Endoscopy, Gastrointestinal
  • Gastrointestinal Diseases / chemically induced*
  • Gastrointestinal Diseases / diagnosis
  • Gastrointestinal Diseases / therapy
  • Humans
  • Mexico
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal